Motley Fool
0
All posts from Motley Fool
Motley Fool in Motley Fool,

Why Shares of Relypsa Are Soaring Today

Image Source: Getty Images.

What: Relypsa (NASDAQ: RLYP), a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica Group bought the drugmaker in an all-cash deal for $32 per share, or about $1.53 billion. 

So what: Once this deal closes in the third quarter of this year, Galenica will gain access to Relypsa's FDA-approved treatment for hyperkalemia known as Veltassa (patiromer). Now that AstraZeneca's (NYSE: AZN) competing hyperkalemia therapy, ZS-9, has been rejected by the agency for manufacturing problems, Veltassa appears to be in prime position to take control of this nearly $6 billion market moving forward..

Perhaps the bigger issue is that some analysts initially pegged Veltassa's peak sales at a mere $200 million due to the presumed near-term entrance of Astra's rival drug. But with ZS-9 out of the picture for the time being, the Street now thinks Veltassa should have enough time as the go-to treatment to achieve blockbuster status.

Now what: Galenica plans to use the acquisition of Relypsa as a springboard to break the company up into two separate companies in 2017. Specifically, Relypsa will be rolled into Galenica's business unit Vifor Pharma, which is expected to be spun off into a publicly listed specialty pharmaceutical company focused on nephrology, cardiology, and gastroenterology medicines. So investors will presumably have yet another chance to invest in Relypsa's novel hyperkalemia drug by purchasing shares of the forthcoming spin-off next year. Stay tuned. 

A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.